coronavirus treatment

U.S. regulators have ended one of Eli Lilly’s COVID-19 antibody trials early after data suggested the drug was “unlikely to help” coronavirus patients recover.

The World Health Organization released the findings of their coronavirus therapeutics study on Friday, which studied the impact of drugs like remdesivir and hydroxychloroquine on treating hospitalized coronavirus patients.

Eli Lilly’s late-stage trial of its monoclonal antibody coronavirus treatment was paused by U.S. regulators over potential safety concerns.

President Donald Trump briefly left Walter Reed Medical Center in his motorcade to salute at supporters outside the hospital. Trump was admitted to Walter Reed for COVID treatment on Friday. Doctors have said the president is doing “well” and could return to the White House as early as Monday.

Doctors treating President Donald Trump for the coronavirus at Walter Reed Medical Center gave updates on the president’s treatment on Saturday morning. “At this time, the team and I are extremely happy with the progress the president has made,” said the president’s physician, Dr. Sean Conley.

With 74-year-old President Trump and 50-year-old first lady Melania Trump testing positive for the coronavirus, what are the best proven treatments for them and other patients?

The nearly 1 million people who have lost their lives to COVID-19 also have given the world a gift: a better understanding of how to treat the disease.

Hospitals across Florida are struggling to keep some of the most promising therapies on hand.  Just this week, Gov. Ron DeSantis promised local hospitals that more Remdesivir is on the way.  “The supplies have been limited,” said DeSantis. “We’ve worked very closely with the White House to be able to continue replenishing the supply of Remdesivir.” Meanwhile, there continues...

There continues to be hope for more treatment options, including one that doctors say is readily available, a fraction of the price and backed by a big study — a steroid called dexamethasone. NBC 6’s Alyssa Hyman reports.

Pharmaceutical giant Gilead says it plans to charge at least $2,300 for a single treatment course of Remdesivir, a drug shown to shorten recovery time for severely ill coronavirus patients.

A new study out of the University of Minnesota suggests that anti-malarial drug hydroxychloroquine has no effect on preventing patients from contracting the novel coronavirus.

Results from a phase three trial show that Remdesivir helps recovery in moderately-ill coronavirus patients.

At a press conference on Monday, Admiral Brett Giroir, assistant secretary for health, confirmed that HHS is working with a network of children’s hospitals and intensive care units to better understand the extreme coronavirus symptoms in infected children.

When asked if he takes responsibility for the spike in calls to poison control centers around the country following his on-camera comments about bleach and disinfectant injection as a potential coronavirus treatment, President Donald Trump said, “I can’t imagine why.”

Faced with long odds of survival for COVID-19 patients put on respirators, doctors find alternatives may work better for some.

Ever since the first COVID-19 patients were treated in China, many doctors have assumed ventilators are called for when oxygen levels get so low, they fear a patient could soon die. But now, emergency room doctors in the US are having second thoughts. NBC 6’s Tony Pipitone reports.

Singer Jon Bon Jovi paid a digital visit this week to a kindergarten class, where he helped students strengthen their songwriting skills.

As patients with COVID-19 continue pouring into emergency departments and intensive care units across the nation, an old treatment that has been adapted for a new disease is now being tested in New York, NBC News reports.